Publications by authors named "Luke Akard"

Claim this Profile
I
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation.
Christopher Strouse, Mark Juckett, Brent R Logan, Noel Estrada-Merly, Andrew Peterson, Luke P Akard

JCO Oncol Pract· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemigatinib for Myeloid/Lymphoid Neoplasms with Rearrangement.
Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Jay L Patel, Alessandro Rambaldi, Luke P Akard

NEJM Evid· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers.
Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E Lehmann, Hemalatha G Rangarajan, Luke P Akard

Transplant Cell Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Pinkal M Desai, Janice Brown, Saar Gill, Melham M Solh, Luke P Akard

J Clin Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.
Johan Maertens, Aaron C Logan, Junho Jang, Gwynn Long, Jih-Luh Tang, Luke Akard

Antimicrob Agents Chemother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of Publicly Reported Center Outcomes into Standards and Accreditation: The FACT Model.
Charles F LeMaistre, Kara K Wacker, Luke P Akard, A Samer Al-Homsi, Dennis A Gastineau

Biol Blood Marrow Transplant· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Michael A Pulsipher, Brent R Logan, Deidre M Kiefer, Pintip Chitphakdithai, Marcie L Riches, Luke P Akard

Haematologica· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Michael A Pulsipher, Brent R Logan, Pintip Chitphakdithai, Deidre M Kiefer, Marcie L Riches, Luke P Akard

Biol Blood Marrow Transplant· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S Wertheim, William J Edenfield, Luke Akard

Blood· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.
Pradnya Chopade, Luke P Akard

Clin Lymphoma Myeloma Leuk· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Lauren E Caldemeyer, Luke P Akard, John R Edwards, Anand Tandra, Dawn R Wagenknecht

Biol Blood Marrow Transplant· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.
Sikander Ailawadhi, Luke P Akard, Carole B Miller, Anand Jillella, Daniel J DeAngelo

Ther Adv Hematol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Luke Akard, Hagop M Kantarjian, Franck E Nicolini, Meir Wetzler, Jeffrey H Lipton

Leuk Lymphoma· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Lauren Caldemeyer, Luke P Akard

Leuk Lymphoma· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Luke P Akard, Dale Bixby

Leuk Lymphoma· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Jorge E Cortes, Jeffrey H Lipton, Carole B Miller, Lambert Busque, Luke P Akard

Clin Lymphoma Myeloma Leuk· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Lauren Caldemeyer, Michael Dugan, John Edwards, Luke Akard

Curr Hematol Malig Rep· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Jorge E Cortes, Hagop M Kantarjian, Delphine Rea, Meir Wetzler, Jeffrey H Lipton, Luke Akard

Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Stuart L Goldberg, Luke P Akard, Michael J Dugan, Stefan Faderl, Andrew L Pecora

J Oncol Pract· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
H Jean Khoury, Jorge Cortes, Michele Baccarani, Meir Wetzler, Tamas Masszi, Luke Akard

Leuk Lymphoma· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Luke P Akard, Jorge E Cortes, Maher Albitar, Stuart L Goldberg, Ghulam Warsi

Arch Pathol Lab Med· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Jorge E Cortes, Franck E Nicolini, Meir Wetzler, Jeffrey H Lipton, Luke Akard

Clin Lymphoma Myeloma Leuk· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Franck E Nicolini, H Jean Khoury, Luke Akard, Delphine Rea, Hagop Kantarjian

Haematologica· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.
Elias J Jabbour, Dale Bixby, Luke P Akard

Clin Adv Hematol Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag in refractory aplastic anemia.
Luke Akard

N Engl J Med· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis